Table 3. Risk factors for acquiring any opportunistic infection in a cohort of patients on ART followed up for 10 years.

Variable		Univariate analysis	p	Multivariate analysis	p
Baseline age
	Per 5 years increase	0.88 (0.80–0.97)	0.012	0.94 (0.85–1.04)	0.243
Gender
	Male	1.00
	Female	1.16 (0.82–1.63)	0.402
Baseline WHO stage
	1 or 2	1.00		1.00
	3 or 4	2.25 (1.19–4.26)	0.013	1.58 (0.81–3.07)	0.179
Baseline CD4 cell count
	>100 cells/μL	1.00		1.00
	50–100 cells/μL	1.13 (0.72–1.77)	0.609	0.85 (0.52–1.40)	0.525
	<50 cells/μL	1.65 (1.18–2.30)	0.004	0.83 (0.54–1.28)	0.401
Baseline viral load
	<5 log copies/μL	1.00
	≥5 log copies/μL	1.14 (0.78–1.68)	0.502
Baseline regimen
	Nevirapine-based	1.00		1.00
	Efavirenz-based	0.74 (0.51–1.07)	0.107	0.56 (0.37–0.83)	0.004
Baseline BMI
	≥18.5 kg/m2	1.00
	<18.5 kg/m2	1.09 (0.78–1.52)	0.628
Baseline hemoglobin
	>11 g/dL	1.00		1.00
	8–11 g/dL	1.62 (1.17–2.23)	0.003	0.95 (0.65–1.38)	0.779
	<8 g/dL	2.01 (1.04–3.87)	0.037	1.18 (0.55–2.53)	0.661
Current CD4 cell count
	Per 50 cells/μL increase	0.70 (0.64–0.76)	<0.001	0.90 (0.81–1.00)	0.050
Current viral load
	Per 1 log increase	2.78 (2.41–3.20)	<0.001	2.42 (2.05–2.85)	<0.001
Current regimen
	First-line regimen	1.00
	Second-line regimen	1.26 (0.29–5.43)	0.754
Current BMI
	Per 1 kg/m2 increase	0.88 (0.83–0.93)	<0.001	0.95 (0.90–1.00)	0.071
Current hemoglobin
	Per 1 g/dL increase	0.76 (0.70–0.82)	<0.001	0.90 (0.81–1.00)	0.045

ART: antiretroviral therapy; BMI: body mass index; WHO: World Health Organization